News‎ > ‎

Cannabis Focus

The cannabis legalization trend sweeping across the Western hemisphere and Australia is causing many entrepreneurs to re-evaluate their current business outlook and seriously consider entering the cannabis sector. The emerging cannabis sector is ripe with opportunity for entering and an industry that is at its infancy. Not unlike the post-prohibition era in the United States subsequent to the passing of the 21st-amendment ending prohibition in 1933, there are many very successful alcoholic beverage businesses that exist to this day, that were upstarts by visionary entrepreneurs that, despite the uncertainty at the time, went ahead and “took the plunge.” WEED Inc, formerly known as United Mines, Inc., is one such Company that has transitioned from the precious metals mining sector, to the cannabis sector.

WEED Inc (OTCMKTS:BUDZ) is a USA based public company. WEED Inc is a multi-national, multi-faceted, vertically integrated World Class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly owned subsidiaries and strategically placed collaborative partners to achieve & promote our Global Brand. WEED is dedicated to its Global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant. WEED will contract its own team of world respected specialized Medical Doctors, geneticists, scientists, engineers, technicians and farming consultants. This unison collaborates decades of expertise and innovative working knowledge in the fields of genetics and phytochemistry, together with botany and ecology, sustainability and bacteriology environmentalists, agronomy and permaculture specialists, in addition to utilizing the worlds latest technological advances in growing equipment and facilities, seed pollination, propagation and cultivation; cloning and cross breeding,  genetic testing and germplasm storage, cloning and germplasm genetic storage.

WEED Inc. purchases land and builds commercial grade “cultivation & research centers” to consult, assist, manage & lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical cannabis sector. The Company’s plan is to become a true “Seed-to-Sale” global brand providing infrastructure, financial solutions, medical research and education, along with real estate solutions in this new emerging market.

On January 24, 2017, WEED, Inc. announced that it formed a wholly-owned subsidiary in Australia, namely WEED AUSTRALIA LTD. The new Australian Company plans to list on the Australian Securities Exchange (ASX) in coming months. Australia recently legalized Medicinal Cannabis for strain specific/disease specific, cannabis research. Cannabis and Hemp product development and manufacturing are part of the research process. WEED’s Australian subsidiary plans to apply for all seven cannabis research, processing and product, import/export and manufacturing licenses available, with variations, along with Cannabis and Hemp import/export in the coming months. Additionally, WEED AUSTRALIA LTD. plans to form The Cannabis Institute of Australia. The Institute will be a non-profit arm that will apply for Cannabis research permits state-by-state in Australia, including both North and South Territories.

On May 24, 2017, WEED Inc announced the acquisition of Sangre AT, LLC (dba “Sangre AgroTech”) as a wholly-owned subsidiary of WEED. Sangre AgroTech’s world-respected team brings to the table decades of expertise and innovation in the fields of genetics, plant biology, plant pathology, phytoecology, and sustainable and environmentally sound agricultural practices. The development and application of cannabis-derived compounds for the treatment of human disease is what the AgroTech research team will focus on. Sangre’s research team will develop the required scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines by targeting cannabis-derived molecules which stimulate the endocannabinoid system. WEED’s Co-Founder and CEO, Glenn E. Martin commented:

“Cannabis Research and Education are keys to WEED’s long term strategic plan for our sector. As WEED’s first major acquisition, the ‘Brain Trust’ of our dedicated staff of PhDs at Sangre AgroTech will prove instrumental in achieving WEED’s goal of creating NEW strain-specific, disease-specific treatments and cures over the next several years. Several patentable strains, along with accompanying THC and CBD compounds, look to be developed and achievable in our 5-year time frame.”

WEED AUSTRALIA LTD. will work closely with Sangre AgroTech LLC, a U.S.-based entity that has begun a 5-year, $10 million Cannabis Genomics Study for the purpose of completing a global genomic classification of the cannabis plant genus.